Other promising developments include albumin–insulin conjugates for diabetes management, which leverage albumin’s prolonged half-life to achieve sustained glucose control, as well as albumin-bound photosensitizers for photodynamic cancer therapy. The gene discussed is INS; the disease is diabetes mellitus.